Asia-Pacific + Japan in Parallel — Locating the "Five-Layer Net" Internationally— Korea's KPBMA · China's NMPA · Australia's Medicines Australia, set beside Japan to make shared and country-specific elements visible

01Why Read the Asia-Pacific Region

The Asia-Pacific region is expanding rapidly in both pharmaceutical market scale and regulatory diversity. Japan's neighbors — Korea, China, Taiwan, Hong Kong, Singapore, Malaysia, Thailand, Indonesia, India, Australia, and New Zealand — each have distinct underlying regulatory philosophies. As a region, however, they share reference points — ICH guidelines (= international rules that align how the U.S., EU, and Japan approve drugs), WHO norms (= guidance from the World Health Organization), the U.S. FDA (= Food and Drug Administration), and the European EMA (= European Medicines Agency) — and they have evolved on top of these in their own ways.

This piece narrows to four representative countries — Japan, Korea, China, Australia — chosen for the combination of market scale and regulatory maturity. India (the world's third-largest pharmaceutical producer) is critical, but for a structural comparison these four form a compact microcosm of regional diversity.

02The Four-Country Regulatory Overview

03The Shared — Four Principles That Cross Borders

Lined up, the four systems differ in expression and execution but share four common principles. These are sediment from ICH, WHO, EU, and FDA norms working their way into the region.

1. Conformity with the Marketing Authorization — Advertising and promotion exceeding the approved scope is prohibited in principle. Japan §68, KPBMA Code §4, China advertising rules §10, MA Code §1.3.
2. Prescription DTC restriction (DTC = Direct-to-Consumer, advertising aimed at the general public — patients and consumers — rather than at doctors) — Japan, Korea, China, and Australia all prohibit prescription-drug advertising to the general public in principle. Australia permits limited "reminder" advertising (= naming the product only, with no efficacy claims) but disallows explicit efficacy claims. No Asia-Pacific country permits U.S.-style full DTC (= the kind that states efficacy too).
3. Prohibition on money or money-equivalent gifts to HCPs — Every industry code and statute among the four bars gifts of money or monetary equivalents. Permitted items must have educational value, subject to annual caps.
4. Disclosure of payments and benefits — Korea and Australia operate explicit payment-disclosure regimes (Sunshine type — a system that brings money paid by drug companies to doctors into the open, named after the U.S. Sunshine Act). Japan is advancing gradually via JPMA guidelines. China is moving in the same direction via the CPIA (= China Pharmaceutical Industry Association) industry channel.

04The Distinctive — Five Asia-Specific Characteristics

On top of the shared principles, each country layers its own. Five characteristics distinctive of the Asia-Pacific region:

• Japan — depth of the public-norm layering: The four public layers — statute (Pharmaceutical Act) → public notice (Advertising Appropriateness Standards) → administrative guideline (HanteiG) → industry self-regulation (JPMA Code / Creation Guidelines) — sit alongside the U.S. (4 layers + case law) and Europe (3 tiers: supranational / national / industry) as the comparable architecture. The colloquial "five-layer net" adds each company's internal SOPs as a fifth layer, but since companies in the U.S., Europe, Korea, China, and Australia all maintain equivalent internal SOPs, the comparison table here uses public norms only.
• Korea — interlocking with antitrust law (KFTC): The KPBMA Fair Trade Code lives under KFTC authorization, producing a double-sanction structure where "violating advertising rules is also an antitrust violation." Globally unusual.
• China — specialist-publication restriction + government publication: Statutorily restricts prescription-drug advertising media to "specialist medical publications," prohibiting all other channels. The government routinely publishes violating companies and the specifics of violations. Closely resembles U.S. OPDP Warning Letter style.
• Australia — coordinated industry + federal regulation: A coordinated model between TGA (government) and Medicines Australia (industry). The industry Code functions as the de facto first stop; TGA is the final legal authority. Resembles the UK ABPI (= the British pharmaceutical industry body) / MHRA (= the UK medicines regulator) model.
• Japan — per-medium granularity of the JPMA Creation Guidelines: Japan's industry-level Creation Guidelines specify granular per-medium craft for product information summaries, specific PI summaries, advertorials, roundtables, lecture record collections, disease awareness materials, patient materials — among the most highly subdivided industry self-regulation in the world.

05Korea — KPBMA Fair Trade Code in Detail

Korea's KPBMA Fair Trade Code (공정거래자율준수규약) is an industry code operating under the framework of antitrust law. First version in 1995, multiple revisions; current version 2024.

Key features:

• Scope — KPBMA member companies plus foreign-affiliated pharmaceutical companies (effectively almost all major players).
• Principal prohibited practices — Improper provision of benefits, unfounded efficacy claims, unfair comparison with competitors, off-label promotion (= promoting use beyond the approved indication or method), inappropriate economic ties with HCPs.
• KFTC authorization — As an industry code authorized by the KFTC, violations are sanctioned as antitrust violations — surcharges (= monetary penalties imposed by the regulator) and business-suspension orders.
• Public violation announcements — KPBMA's ethics committee reviews violations and publicly announces the violator and the sanction. An annual list of violators is published on the website.
• Transparency — Since 2018, mandatory annual disclosure of all economic benefits from pharmaceutical companies to HCPs and HCOs (Sunshine type).

06China — NMPA Regulation: Statutory Architecture and Operational Distinctiveness

China's pharmaceutical advertising regulation is rapidly tightening. The 2015 revised Advertising Law (Advertising Law of the People's Republic of China, revised version) opened the current phase of major reform. The 2020 Medical Products, Devices, and Advertising Administration Rules (issued by NMPA) systematized specific operational rules for pharmaceutical advertising.

Key features:

• Media restriction for prescription drugs — Prescription drug advertising is restricted to HCP-directed specialist medical publications (Advertising Law §15). Advertising in general media, the internet, or social platforms is fully prohibited.
• Pre-clearance (filing system) (= a registration system where the ad is filed with and recorded by the authority before release) — Before advertising can be deployed, pre-clearance and filing with SAMR are required (including OTC). Deployment without approval triggers fines and stop-distribution orders.
• Government publication of violators — NMPA and SAMR publish violating companies and details on their official websites. Resembles the U.S. OPDP Warning Letter model.
• Strict penalties — Violations attract fines (3–5 times the advertising spend), business-suspension orders, and possible revocation of marketing authorization. Serious violations can attract criminal liability.
• Cross-border advertising regulation — Advertising originating overseas (via cross-border e-commerce or foreign web media) is treated as subject to Chinese law in practice.

07Australia — The Medicines Australia Code: Industry-Government Coordination

Australia's regulation is built on coordination between industry self-regulation (Medicines Australia Code of Conduct) and federal regulation (Therapeutic Goods Act + TGA). Structurally close to the UK ABPI + MHRA model.

Key features of the Medicines Australia Code (Edition 20, 2024):

• Pre-vetting systems (= checks before release) — Mandatory pre-release review by a medical officer (= a physician inside the company) of prescription-drug materials aimed at HCPs (= healthcare professionals — doctors, pharmacists, and the like). Some Direct-to-Healthcare-Professional (DTHP, = delivered straight to healthcare professionals) materials are also subject to pre-clearance by MA's Code of Conduct Committee.
• Disclosure of Transfers of Value (= public disclosure of the money and goods — the "value" — that moves to doctors) — Annual public disclosure of payments and gifts from pharmaceutical companies to HCPs and HCOs (= healthcare organizations) (introduced 2015, Sunshine type).
• Off-Label exception — Provision of off-label information is permitted in response to unsolicited questions (= where the HCP asks first, on their own initiative) from HCPs (same shape as the UK ABPI Code).
• Public violation adjudication — The Code of Conduct Committee publicly adjudicates violations. Violating company name, breach, and sanction (fines up to AUD 200,000, Public Reprimand, etc.) are published on the MA website.
• Coordination with TGA — Where an industry-code breach is also a statutory breach, TGA investigates and sanctions in parallel.

08The Final Four-Way Comparison — U.S. / Europe / Japan / Asia (KR-CN-AU)

As the series conclusion, the U.S. (Overseas 01), Europe (Overseas 02), Japan, and the rest of Asia (this piece) consolidated into one table.

09Locating Japan's "Five-Layer Net" Internationally — The Series Conclusion

Putting the full series together, Japan's "five-layer net" can be located internationally as follows.

① The "stacking" approach is European

Japan's four public layers (statute → public notice → administrative guideline → industry self-regulation) rest on the same idea as Europe's three-tier structure (EU / nation / industry) — higher norms refined by lower norms, multi-layer stacking. It is structurally different from the U.S. (4 layers + dynamic case-law adjustment). The 1979 revision of the Pharmaceutical Affairs Act (the response to thalidomide) imported many European elements; that historical path produced this structure.
※ The fifth layer of the colloquial "five-layer net" is each company's internal SOPs — an internal implementation present at companies in the U.S., Europe, and Asia alike. For international comparison, this article uses public norms only.

② Central concept is "public-health protection"

U.S. Fair Balance (= the rule on "the structure of expression," requiring efficacy and risk to be shown in balance, both sides together) prescribes "the structure of expression." Japan's §66 lays out "a list of prohibited acts." This places Japan in the same family as Europe (SmPC — the official package insert / product summary for a medicine — consistency + rational use) and Korea / China / Australia — a design philosophy that places public-health protection above freedom of expression. The U.S. is the special position with its strong First Amendment protection of speech.

③ Off-Label and DTC are the most strictly handled

On prescription DTC (= advertising aimed directly at the general public) and Off-Label promotion (= promoting use beyond the approved scope), Japan sits at the strictest end among the U.S., Europe, and the four Asia-Pacific systems. Japan accepts neither the U.S. "Caronia exception" (= a U.S. court ruling that, within limits, treated truthful off-label information as protected free speech) nor the UK / Australia "unsolicited request exception" (= an exception that lets a company answer only when a doctor asks first, on their own initiative) — full prohibition under §68. This is the historical choice in light of the second-largest thalidomide casualty count in the world.

④ The "non-public" character of enforcement is Japan's distinctive

The U.S. (OPDP Warning Letters — OPDP is the FDA's ad-monitoring office; a Warning Letter is its formal notice of violation), Europe (PMCPA — the UK industry ad-review body / FSA — the French industry transparency body), Korea (KPBMA), China (NMPA), Australia (MA Code Committee) — all of these jurisdictions publicly disclose violating companies and details. Japan is nearly alone in keeping enforcement non-public in principle. A deliberate design choice that prioritizes "individual company self-improvement" over "deterrence across the industry." Whether this remains right is open to debate.

⑤ Per-medium granularity is world-leading

The granular per-medium craft set out in the JPMA Creation Guidelines — more than eight distinct review disciplines across product information summaries, specific PI summaries, advertorials, roundtables, lecture records, disease awareness materials, patient materials, case reports — is among the most highly subdivided industry self-regulation in the world. This is a heritage that material reviewers can take genuine pride in.

10Connections to Other Chapters on This Site

This Asia-Pacific + Japan parallel analysis connects to other parts of the site:

• The International Lens 01 — United States — The U.S. "4 layers + case law."
• The International Lens 02 — Europe — The European 3-tier structure as a starting point.
• Yakugai History 02 — Thalidomide — Japan's position as second-worst affected country, and the 1979 Pharmaceutical Affairs Act revision that imported European elements.
• Material Review Vol. 2 — Japan's five-layer net in detail.
• Ad Regulations 01 — Pharmaceutical Act §§66–68 and the foundation for international comparison.
• Material Review Part 7 (per-medium) — The Japan-specific per-medium granularity.